ATE235513T1 - Opioid-konjugate mit endogenen trägerproteinen - Google Patents

Opioid-konjugate mit endogenen trägerproteinen

Info

Publication number
ATE235513T1
ATE235513T1 AT01121557T AT01121557T ATE235513T1 AT E235513 T1 ATE235513 T1 AT E235513T1 AT 01121557 T AT01121557 T AT 01121557T AT 01121557 T AT01121557 T AT 01121557T AT E235513 T1 ATE235513 T1 AT E235513T1
Authority
AT
Austria
Prior art keywords
patient
conjugates
antinociceptive
conjugate
vivo
Prior art date
Application number
AT01121557T
Other languages
English (en)
Inventor
Alan M Ezrin
Dominique P Bridon
Darren L Holmes
Peter Milner
Original Assignee
Conjuchem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conjuchem Inc filed Critical Conjuchem Inc
Application granted granted Critical
Publication of ATE235513T1 publication Critical patent/ATE235513T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01121557T 1997-11-07 1998-11-06 Opioid-konjugate mit endogenen trägerproteinen ATE235513T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6470597P 1997-11-07 1997-11-07

Publications (1)

Publication Number Publication Date
ATE235513T1 true ATE235513T1 (de) 2003-04-15

Family

ID=22057753

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01121557T ATE235513T1 (de) 1997-11-07 1998-11-06 Opioid-konjugate mit endogenen trägerproteinen
AT98956656T ATE216402T1 (de) 1997-11-07 1998-11-06 Opioid-konjugate mit endogenen trägerproteinen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT98956656T ATE216402T1 (de) 1997-11-07 1998-11-06 Opioid-konjugate mit endogenen trägerproteinen

Country Status (9)

Country Link
EP (2) EP1007561B1 (de)
JP (2) JP2001522863A (de)
AT (2) ATE235513T1 (de)
AU (3) AU750387B2 (de)
CA (2) CA2301799C (de)
DE (2) DE69804974T2 (de)
ES (1) ES2173641T3 (de)
IL (1) IL135835A0 (de)
WO (3) WO1999024076A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437092B1 (en) 1998-11-06 2002-08-20 Conjuchem, Inc. Conjugates of opioids and endogenous carriers
WO1999048536A2 (en) * 1998-03-23 1999-09-30 Conjuchem, Inc. Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DK2319928T3 (da) 1998-10-23 2013-06-24 Kirin Amgen Inc Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet
SI1105409T1 (sl) * 1999-05-17 2006-06-30 Conjuchem Inc Zascita endogenih peptidov pred peptidazno ucinkovitostjo s konjugacijo na krvne komponente
EP1180121B9 (de) 1999-05-17 2004-09-08 Conjuchem, Inc. Lang wirkende insulinotrope peptide
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US7144854B1 (en) 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
CA2372338A1 (en) * 1999-05-17 2000-11-23 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
JP4209086B2 (ja) * 1999-05-17 2009-01-14 コンジュケム バイオテクノロジーズ インコーポレイテッド 長期持続性抗新脈管形成ペプチド
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
BR0206919A (pt) 2001-02-02 2004-07-06 Conjuchem Inc Derivados de fator de liberação de hormÈnio de crescimento de longa duração
AU2002233089B2 (en) 2001-02-16 2005-12-22 Conjuchem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
DE60216151T2 (de) 2001-05-31 2007-09-27 ConjuChem Biotechnologies Inc., Montreal Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
US7927579B2 (en) 2003-01-17 2011-04-19 Advanced Proteome Therapeutics, Inc Tandem analyses of noncovalently driven effectors for modulatory mapping of activities of protein sites
ES2328591T3 (es) 2004-04-23 2009-11-16 Conjuchem Biotechnologies Inc. Procedimiento para la purificacion de conjugados de albumina.
CA2572765C (en) 2004-07-08 2013-05-21 Amgen Inc. Compound having improved bioefficiency when administered in a multidose regimen
CN101103045B (zh) 2004-09-24 2015-11-25 安姆根有限公司 修饰的Fc分子
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
US7982018B2 (en) 2006-10-16 2011-07-19 Conjuchem, Llc Modified corticotropin releasing factor peptides and uses thereof
GB201204868D0 (en) 2012-03-20 2012-05-02 San Raffaele Centro Fond Peptides
WO2016011319A1 (en) * 2014-07-18 2016-01-21 Biocogent, Llc Compositions and methods comprising salicylates and polysalicylates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59138958A (ja) * 1983-01-31 1984-08-09 Mitsubishi Chem Ind Ltd 抗血清
US4784955A (en) * 1984-09-21 1988-11-15 Miles Inc. Immunogen conjugates and the use thereof in a dihydropyridine assay
IE901736L (en) * 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
DK608589D0 (da) * 1989-12-01 1989-12-01 Holm Arne Kemisk fremgangsmaade
US5292362A (en) * 1990-07-27 1994-03-08 The Trustees Of Columbia University In The City Of New York Tissue bonding and sealing composition and method of using the same
JPH04364200A (ja) * 1991-06-10 1992-12-16 Unitika Ltd 細胞接着性アルブミン
US5399671A (en) * 1992-11-18 1995-03-21 Kluger; Ronald Specifically crosslinked hemoglobin with free functionality
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes

Also Published As

Publication number Publication date
AU1312799A (en) 1999-05-31
DE69812727D1 (de) 2003-04-30
CA2301799A1 (en) 1999-05-20
AU1385699A (en) 1999-05-31
AU750387B2 (en) 2002-07-18
ATE216402T1 (de) 2002-05-15
AU1519799A (en) 1999-05-31
WO1999024076A9 (en) 2000-06-08
EP1007561A2 (de) 2000-06-14
CA2309205A1 (en) 1999-05-20
WO1999024074A2 (en) 1999-05-20
EP1007561B1 (de) 2002-04-17
WO1999024074A3 (en) 1999-08-19
DE69804974T2 (de) 2002-11-07
WO1999024462A2 (en) 1999-05-20
WO1999024076A3 (en) 1999-08-19
WO1999024462A3 (en) 1999-08-26
IL135835A0 (en) 2001-05-20
CA2301799C (en) 2007-08-07
ES2173641T3 (es) 2002-10-16
JP2001522817A (ja) 2001-11-20
WO1999024076A2 (en) 1999-05-20
EP1028971A2 (de) 2000-08-23
DE69804974D1 (de) 2002-05-23
JP2001522863A (ja) 2001-11-20

Similar Documents

Publication Publication Date Title
ATE235513T1 (de) Opioid-konjugate mit endogenen trägerproteinen
Ringsdorf Structure and properties of pharmacologically active polymers
Begley The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system
CA2064689A1 (en) Stabilized protein or peptide conjugates
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
AU2259392A (en) Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
WO1988000834A1 (en) Chimeric peptides for neuropeptide delivery through the blood-brain barrier
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
Poznansky et al. Insulin: carrier potential for enzyme and drug therapy
WO2001060412A3 (en) Modification of biopolymers for improved drug delivery
IL161670A0 (en) Thymosin alpha 1 peptide/polymer conjugates
US5411943A (en) Hepatoma treatment with somatostatin analogs
Habberfield et al. Vitamin B12-mediated uptake of erythropoietin and granulocyte colony stimulating factor in vitro and in vivo
AU2002238687B2 (en) Compounds comprising an analgesic molecule linked to a vector that can vectorise said molecule through the hematoencephalic barrier and pharmaceutical compositions containing same
IL117564A (en) Pharmaceutical and diagnostic compositions containing lysine derivatives
IL153586A0 (en) Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
Squibb INTROS
ITMI960133A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti colostro e uso del colostro per il trattamento di disfunzioni erettili
MD1135F1 (en) Paradontium treatment method
CA2326720A1 (en) Hemoglobin-haptoglobin complexes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties